Back to results
US 8,802,679 B2Granted
Glycine compound
AssigneeAstellas Pharma Inc.
InventorsKousei Yoshihara, Daisuke Suzuki, Susumu Yamaki, Yuji Koga, Norio Seki, Jiro Fujiyasu, Masahiro Neya
Life of this patent
Estimating the term…
Abstract
Compounds of formula (I) defined herein exhibit VAP-1 inhibitory activity, and as a result, are useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention.
Claims12
A compound represented by the formula (I) or a salt thereof:
- wherein
- R1 is H or lower alkyl which may be substituted with halogen,
- R2 is halogen,
- R3 and R4 are the same as or different from each other, and are H or halogen,
- m is 0, 1, 2, 3, or 4,
- Y1 and Y2 are both N,
- X is Z—,
- Z is
- R21, R22, R23, R24, R25 and R26 are H, Y4 is N or CRY41, Y5 is N or CRY51, RY41, RY51, and RG32 are H, halogen, —OH, —O-lower alkyl (in which the lower alkyl may be substituted with 1 to 3 OH, halogen, —O-lower alkyl (in which the lower alkyl may be substituted with one or more —COOH groups), or aryl groups), —CHO, —CO-lower alkyl (in which the lower alkyl may be substituted with 1 to 3 halogen atoms), —CO-cycloalkyl (in which cycloalkyl may be substituted with one or more —O-lower alkyl groups), —CO-aryl, a —CO-monocyclic saturated hetero ring group, cyano, —COOH, —COO-lower alkyl (in which the lower alkyl may be substituted with 1 to 3 halogen atoms), lower alkyl which may be substituted with —COOH or —O-lower alkyl, or lower alkenyl which may be substituted with —COOH or —O-lower alkyl, and s is 0, 1, 2, or 3.
6 more elements
Dependencies are inferred from the claim text.